Vilanterol

Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). . The combination is also approved for the treatment of asthma in Canada, Europe, Japan and New Zealand.

Vilanterol is available in following combinations:


 * with inhaled corticosteroid fluticasone furoate—fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S., NZ), Relvar Ellipta (EU, RU, JPN) )
 * with muscarinic antagonist umeclidinium bromide—umeclidinium bromide/vilanterol (trade name Anoro Ellipta)
 * with inhaled corticosteroid fluticasone furoate and muscarinic antagonist umeclidinium bromide—fluticasone furoate/umeclidinium bromide/vilanterol (trade name Trelegy Ellipta)